Quarterly ResultMay 11, 2026, 09:02 AM
MoonLake Immunotherapeutics Q1 Net Loss Widens to $69.7M
AI Summary
MoonLake Immunotherapeutics reported a significant increase in net loss for the first quarter of 2026, reaching $69.7 million, compared to $40.6 million in the same period last year. This was primarily driven by higher research and development expenses, which rose to $54.5 million. The company's cash and cash equivalents decreased to $298.5 million, but management believes it has sufficient capital to fund operations until the end of 2027, partly due to an amended $500.0 million credit facility.
Key Highlights
- Net loss widened to $69.7 million for Q1 2026, up from $40.6 million in Q1 2025.
- Operating loss increased to $70.0 million in Q1 2026 from $47.5 million in Q1 2025.
- Research and development expenses rose to $54.5 million in Q1 2026 from $36.5 million in Q1 2025.
- General and administrative expenses increased to $15.5 million in Q1 2026 from $11.0 million in Q1 2025.
- Cash and cash equivalents were $298.5 million as of March 31, 2026, down from $334.5 million at December 31, 2025.
- Long-term debt increased to $99.0 million as of March 31, 2026, from $74.1 million at December 31, 2025.
- Net loss per share was $(0.98) for Q1 2026, compared to $(0.63) for Q1 2025.
- Amended Credit Facility provides up to $500.0 million, with a $25.0 million Tranche 2 loan funded in February 2026.
Price Impact
More from MLTX
More in Quarterly Result